Development of blood biomarkers for Alzheimer's disease using high sensitivity digital ELISA method

2020 Fiscal Year Final Research Report

• Project/Area Number: 18K15461
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 52020:Neurology-related
• Research Institution: National Institutes for Quantum and Radiological Science and Technology (2020); Kyoto Prefectural University of Medicine (2018-2019)
• Principal Investigator: Tatebe Harutsugu 国立研究開発法人量子科学技術研究開発機構, 放射線医学総合研究所 脳機能イメージング研究部, 研究員(任常) (00637027)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: 血液バイオマーカー / 認知症 / リン酸化タウ / 高感度ELISA

Outline of Final Research Achievements

We have introduced Simoa (Single molecular array), an ultrasensitive digital assay technology, to introduce phosphorylated tau (p-tau), one of the Alzheimer's disease (AD) biomarkers, in human blood for the first time in the world. We have developed a quantitative system that can be detected on the order of fg/mL.
In addition to p-tau, we have multicenter blood and cerebrospinal fluid for other core biomarkers of AD, Aβ40, Aβ42, t-Tau (total tau protein), NF-L (neurofilament light chain). Sample measurements were taken. As a result, it was confirmed that all substances can be stably measured with Simoa.

Free Research Field

神経内科学

Academic Significance and Societal Importance of the Research Achievements

我々は、超高感度デジタルアッセイ技術であるSimoaを用いて、ヒトの血液中でアルツハイマー病(AD)バイオマーカーを測定する方法の開発をおこなってきた。
血液検査でAD特異的な物質を測定することに成功している。今後、認知症診断において簡便で安価な検査方法として、この血液バイオマーカーを利用できる可能性がある。